Literature DB >> 31092617

Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.

Nicholas Thatcher, Jerome H Goldschmidt, Michael Thomas, Michael Schenker, Zhiying Pan, Luis Paz-Ares Rodriguez, Valery Breder, Gyula Ostoros, Vladimir Hanes.   

Abstract

Entities:  

Year:  2019        PMID: 31092617     DOI: 10.1158/1078-0432.CCR-19-1098

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  1 in total

1.  Retrospective Indication-Matched Cohort Study of Reference Product and Biosimilar: Bevacizumab Versus Bevacizumab-Awwb.

Authors:  Jennifer Philippon Booth; Jeffrey Pilz
Journal:  Hosp Pharm       Date:  2021-09-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.